|
Oct 9
|
Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ...
|
|
Oct 4
|
Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Aug 12
|
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy
|
|
Aug 12
|
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
|
|
Aug 7
|
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
|
|
Jul 31
|
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
|
|
May 15
|
Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
|
|
May 14
|
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 7
|
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
|
|
Apr 29
|
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
|
|
Mar 27
|
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
|
|
Jan 10
|
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
|
|
Aug 9
|
Q2 2023 Atea Pharmaceuticals Inc Earnings Call
|
|
Aug 8
|
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
|